Marinomed Biotech Aktie 44956022 / ATMARINOMED6
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
06.10.2025 14:56:43
|
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
|
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Strategic Company Decision Ad hoc announcement Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Korneuburg, October 6, 2025 - Ad hoc announcement Following the successful recent capital measures, the Management Board of Marinomed Biotech AG, with the approval of the Supervisory Board, today decided to begin reviewing strategic options for the Marinosolv platform. Depending on the progress of the review, the evaluation process could include strategic partnerships for the two projects Budesolv and Tacrosolv, as well as the involvement of a strategist. Marinomed is working with an experienced consulting firm to support this process.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. End of Inside Information Information and Explanation of the Issuer to this announcement: Ad hoc announcement Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Korneuburg, October 6, 2025 - Ad hoc announcement Following the successful recent capital measures, the Management Board of Marinomed Biotech AG, with the approval of the Supervisory Board, today decided to begin reviewing strategic options for the Marinosolv platform. Depending on the progress of the review, the evaluation process could include strategic partnerships for the two projects Budesolv and Tacrosolv, as well as the involvement of a strategist. Marinomed is working with an experienced consulting firm to support this process.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.
06-Oct-2025 CET/CEST News transmitted by EQS Group. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 2208704 |
| End of Announcement | EQS News Service |
|
|
2208704 06-Oct-2025 CET/CEST
Nachrichten zu Marinomed Biotech AG
|
27.11.25 |
Handel in Wien: ATX Prime fällt zum Handelsende (finanzen.ch) | |
|
27.11.25 |
Schwacher Wochentag in Wien: ATX Prime verliert (finanzen.ch) | |
|
27.11.25 |
Börse Wien in Rot: ATX Prime verbucht am Mittag Abschläge (finanzen.ch) | |
|
27.11.25 |
Börse Wien in Rot: ATX Prime schwächelt zum Start (finanzen.ch) | |
|
26.11.25 |
Börse Wien: ATX Prime zum Ende des Mittwochshandels fester (finanzen.ch) | |
|
26.11.25 |
Börse Wien in Grün: ATX Prime nachmittags fester (finanzen.ch) | |
|
26.11.25 |
Optimismus in Wien: So performt der ATX Prime aktuell (finanzen.ch) | |
|
26.11.25 |
Mittwochshandel in Wien: ATX Prime präsentiert sich zum Start fester (finanzen.ch) |
Analysen zu Marinomed Biotech AG
3 Knaller-Aktien im BX Musterportfolio📈: Broadcom, Quanta Services & ING mit François Bloch
Im BX Morningcall werden folgende Aktien analysiert und erklärt
✅ Broadcom
✅ Quanta Services
✅ ING Group
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Marinomed Biotech AG | 19.00 | -1.55% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI und DAX stabil -- Asiens Börsen uneinheitlichDer heimische Markt sowie der deutsche Leitindex zeigen sich vor dem Wochenende wenig bewegt. Die Märkte in Fernost bewegen sich am Freitag in unterschiedliche Richtungen.